CLINICAL CHARACTERISTICS OF HER2-POSITIVE BREAST CANCER
Vol. 63 No. 4 (2017), EXPERIENCE OF ONCOLOGY CLINICS
Vol. 63 No. 4 (2017)

CLINICAL CHARACTERISTICS OF HER2-POSITIVE BREAST CANCER

EXPERIENCE OF ONCOLOGY CLINICS
https://doi.org/10.37469/0507-3758-2017-63-4-657-659
Published 01.04.2017
Gulya Miryusupova
Tashkent Pediatric Medical Institute, Oncological Clinic of Tashkent City Tashkent, Republic of Uzbekistan
G. Khakimov
Tashkent Pediatric Medical Institute, Oncological Clinic of Tashkent City Tashkent, Republic of Uzbekistan
N. Shayusupov
Oncological Clinic of Tashkent City Tashkent, Republic of Uzbekistan
##article.numberofdownloads## 41
##article.numberofviews## 113
PDF (Русский)

Keywords

HER2/NEU- ГИПЕРЭКСПРЕССИРУЮЩИЙ РАК МОЛОЧНОЙ ЖЕЛЕЗЫ
HER2/NEU-OVEREXPRESSING BREAST CANCER
CLINICAL CHARACTERISTICS

How to Cite

Miryusupova, G., Khakimov, G., & Shayusupov, N. (2017). CLINICAL CHARACTERISTICS OF HER2-POSITIVE BREAST CANCER. Voprosy Onkologii, 63(4), 657–659. https://doi.org/10.37469/0507-3758-2017-63-4-657-659
ACM ACS APA ABNT Chicago Harvard IEEE MLA Turabian Vancouver

Abstract

Breast cancer ranks the first place in the structure of morbidity and mortality from malignant tumors of the female population of the Republic of Uzbekistan. According to data of 598 patients with breast cancer biological features of HER2/ neu-positive breast cancer were studied in 109 (18.2 %) cases/ In addition in 31 cases the immunohistochemical analysis on HER2/neu was established as “+2”, the FISH-test was not conducted. Among patients with HER2/neu-overexpressing breast cancer the patients of the indigenous ethnos (Uzbeks) were 54 %. In general among patients with HER2/neu-positive breast cancer the prevalence of locally advanced forms of the disease was noted. Luminal B with HER2/neu-overexpression (45 %) - the average age of patients was 50.4 ± 13.2 years, the average level of Ki67 was 37.8 % ; HER2/neu-overexpress-ing breast cancer (55 %) - the average age of patients was 51.3 ± 9.2 years, the average level of Ki67 was 47.1 %.
https://doi.org/10.37469/0507-3758-2017-63-4-657-659
##article.numberofdownloads## 41
##article.numberofviews## 113
PDF (Русский)

References

Богатюк М.В., Кайгородова Е.В., Завьялова М.В. и др. Функциональные особенности белка теплового шока 27 кДа (Hsp27) при диссонансе амплификации гена cerbB2/neu и экспрессии рецептора Her2/ neu на мембране опухолевых клеток рака молочной железы // Вопр.онкол. - 2014. - Т. 60. - № 6. - С. 713-717.

Кампова-Полевая Е.Б., Портной С.М. Актуальные аспекты клинической маммологии. - Москва: Авторская академия, 2014. - С. 289- 314.

Насхлеташвили Д.Р., Горбунова В.А., Москвина Е.А. Современные возможности таргентной терапии в лечении больных раком молочной железы с гиперэкспрессией HER-2/neu и с метастатическим поражением головного мозга // Вопр.онкол. - 2013. - Т. 59. - № 3. - С. 347-351.

Семиглазов В.Ф., Божок А.А., Семиглазова Т.Ю. и др. HER2- позитивный рак молочной железы: стандартное и двойное таргентное лечение // Вопр.онкол. - 2013. - Т. 59. - № 3. - С. 341-346.

Семиглазов В.Ф. Рак молочной железы: клинико-экспериментальные исследования // Вопр.онкол. - 2016. - Т. 62. - № 2. - С. 208-213.

Mithin Vinod Shan, Anne E. Wiktor, Reid G. Meyer et al. Change in Pattern oh HER2 Fluorescent in Situ Hybrid-izatione (FISH) Results in Breast Cancer Submitted for FISH Testing: Experience of a Reference Laboratory Using US Food and Drug Administration Criteria and American Society of Clinical Oncology and College of American Pathologists Guidelines // http: // JCO.ascopubs.org/cgi/ doi/10.1200/JC0.2015.61.8983 DOI: 10.1200/JCO.2015.61.8983

Shan S.S., Ketterling R.P, Goets M.P, et al. Impact of American Pathologists guideline recommendation on HER2 interpretation in breast cancer // Hum.Path. -2010. - Vol. 41. - P 103-106.

Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.

© АННМО «Вопросы онкологии», Copyright (c) 2017